USFDA approves Alembic Pharmaceuticals’ Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe

USFDA approves Alembic Pharmaceuticals’ Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe

Overview

  • Post By :

  • Source: AP

  • Date: 26 Dec,2022

26th December, 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Prefilled Syringe. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP. Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of breast cancer. Refer to our label for full indication.

Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US$71 million for twelve months ending Sep 2022 according to IQVIA.

Alembic has received a cumulative total of 179 ANDA approvals (156 final approvals and 23 tentative approvals) from USFDA.

About Author

Related Articles

CIPLA launches CIPPOINT, a point-of-care gadget for non-communicable, infectious, and other disorders.

CIPLA launches CIPPOINT, a point-of-care gadget for non-communicable, infectious, and other disorders.

Alembic Pharmaceuticals gets USFDA tentative approval for 100 mg Acalabrutinib capsules.

Alembic Pharmaceuticals gets USFDA tentative approval for 100 mg Acalabrutinib capsules.

Sirio Pharma Successfully Completes the Acquisition of Best Formulations

Sirio Pharma Successfully Completes the Acquisition of Best Formulations

Alembic Pharmaceuticals’ Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, gain USFDA approval.

Alembic Pharmaceuticals’ Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, gain USFDA approval.

Cipla EU to invest EUR 15 million in ETHRIS, initiating a strategic collaboration

Cipla EU to invest EUR 15 million in ETHRIS, initiating a strategic collaboration

Opportunity for Mary kay research and development: Senior Scientist R&D Compliance

Opportunity for Mary kay research and development: Senior Scientist R&D Compliance

Clinithink and AstraZeneca Launch First of its Kind AI Project Aimed at Detecting Early-Stage Lung Cancer

Clinithink and AstraZeneca Launch First of its Kind AI Project Aimed at Detecting Early-Stage Lung Cancer

ENTOD Pharmaceuticals Launches Week-Long Initiative to Raise Awareness and Recognise the Growing Threat of Myopia in Children

ENTOD Pharmaceuticals Launches Week-Long Initiative to Raise Awareness and Recognise the Growing Threat of Myopia in Children

IOL Chemicals and Pharmaceuticals receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in European market

IOL Chemicals and Pharmaceuticals receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in European market

Alembic Pharmaceuticals announces its first injectable product approval from its General Sterile Facility – Final Approval for Glycopyrrolate Injection USP

Alembic Pharmaceuticals announces its first injectable product approval from its General Sterile Facility – Final Approval for Glycopyrrolate Injection USP